Rob Seitz

Insight Genetics has named Rob Seitz as chief technology officer. As CTO, Seitz will oversee the development and commercialization of Insight's genetic assays for the identification of triple-negative breast cancer using technology licensed out of the Vanderbilt Ingram Cancer Center. Prior to joining Insight, Seitz was senior vice president for technology assessment at Clarient (part of GE Healthcare). He also was co-founder and CEO of Applied Genomics prior to its acquisition by Clarient.